C

Crescendo Biologics Limited

60 employees

Crescendo Biologics is engaged in the development of a proprietary drug portfolio based on their VH antibody fragment platform.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Therapeutics

Date founded

2009

Funding rounds raised

Total raised

$70M

from 25 investors over 25 rounds

C

Crescendo Biologics Limited raised $32M on July 24, 2023

Investors: Quan Capital 泉创资本, Andera Partners, Kreos Capital, Sofinnova Partners and -

C

Crescendo Biologics Limited raised $70M on April 30, 2018

Investors: Quan Capital 泉创资本, Takeda UK Limited, EMBL Ventures, Sofinnova Partners and Andera Partners

C

Crescendo Biologics Limited raised undisclosed on December 16, 2014

Investors: Astellas Venture Capital L.L.C.

C

Crescendo Biologics Limited raised $3.3M on April 3, 2014

Investors: Astellas Venture Capital L.L.C., EMBL Ventures, Sofinnova Partners and Imperial College London

C

Crescendo Biologics Limited raised $28M on December 17, 2013

Investors: Imperial College London, Astellas Venture Capital L.L.C. and Sofinnova Partners

C

Crescendo Biologics Limited raised undisclosed on October 1, 2011

Investors: Future Planet Capital

C

Crescendo Biologics Limited raised $7.3M on January 20, 2010

Investors: Sofinnova Ventures, Russia technology fund, Future Planet Capital and UK Innovation & Science Seed Fund

C

Crescendo Biologics Limited raised $7.1M on October 12, 2009

Investors: Future Planet Capital, Sofinnova Partners and UK Innovation & Science Seed Fund

FAQ